Roche’s Ventana Kappa and Lambda Dual ISH mRNA Probe Cocktail assay can assess more than 60 subtypes of B-cell lymphoma and plasma cell neoplasms on a single tissue slide. Credit: Jonathan Weiss/Shutterstock.

Roche has launched an in vitro diagnostic assay, Ventana Kappa and Lambda Dual ISH mRNA Probe Cocktail assay, in countries that accept the EU CE mark.

The Ventana B-cell lymphoma diagnostic assay is designed to qualitatively detect Kappa mRNA and Lambda mRNA. The test detects the presence of B-cell lymphomas and plasma cell neoplasms in formalin-fixed, paraffin-embedded (FFPE) human bone marrow and lymphoid tissue.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

B-cell lymphoma occurs when some lymphocytes are no longer healthy enough to fight infection. These, in turn, grow out of control and become cancerous and may spread to other organs. One of the most common types of B-cell cancer is Non-Hodgkin Lymphoma, which has an annual age-standardised incidence rate of 5.8 per 100,000 population, per a 2024 study.

The increased sensitivity of the test allows for the assessment of more than 60 subtypes of B-cell lymphoma and plasma cell neoplasms on a single tissue slide. The test can also be performed on small biopsies and formalin-fixed tissue, thereby reducing the need for a fresh tissue sample, which may not be available, especially if lymphoma was not originally suspected.

GlobalData estimates that the market for in vitro diagnostics will grow to more than $35.6bn by 2033. Rapid diagnostics have also increased in popularity, especially following the Covid-19 pandemic.

In April, Roche secured a CE mark for the companion diagnostic, Ventana HER2 (4B5) Rabbit Monoclonal Primary Antibody RxDx, for Daiichi Sankyo and AstraZeneca’s Enhertu (trastuzumab deruxtecan). The test can be used to identify patients with low human epidermal growth factor receptor 2 (HER2) expression. These low HER2 patient patients can best benefit from Enhertu, which has been approved in the EU for the treatment of HER2-positive advanced non-small cell lung cancer (NSCLC), breast cancer – either HER2-positive or HER2-low and HER2-positive gastroesophageal junction adenocarcinoma.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Roche’s blood test portfolio includes multiple immunoassays such as Elecsys HBeAg quant to diagnose and monitor hepatitis B, Anti-HEV IgM and Elecsys Anti-HEV IgG immunoassays for detecting hepatitis E virus (HEV) infections, neurofilament light chain (NfL) test for diagnosing multiple sclerosis and interleukin 6 (IL-6) immunoassays for diagnosing neonatal sepsis.